drugset / Trial / NCT05594680

Cilostazol and Methotrexate in Rheumatoid Arthritis

NCT05594680

Phase 3 Unknown 70 enrolled Tanta University
RandomizedParallel-groupTriple-blindTreatment

Summary

This study aims at evaluating the therapeutic effects of Cilostazol as adjuvant therapies to low dose of Methotrexate in patients with Rheumatoid Arthritis and to evaluate their impact on Cyclic adenosine monophosphate(CAMP), Heme Oxygenase-1(HO-1).

Timeline

Start
2022-10-01
Primary completion
2024-11-01
Completion
2024-11-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cilostazol Small molecule 50 mg
Comparator Methotrexate Small molecule 7.5 mg Intramuscular

Indications